A Trial to Evaluate Efficacy and Safety of the Combination Therapy of Genexol-PM Plus Carboplatin® Compared to Genexol Plus Carboplatin® as a Firstline Treatment in Subjects With Ovarian Cancer.
Phase of Trial: Phase II
Latest Information Update: 12 May 2017
At a glance
- Drugs Paclitaxel (Primary) ; Carboplatin
- Indications Ovarian cancer
- Focus Registrational; Therapeutic Use
- Sponsors Samyang Biopharmaceuticals Corporation
- 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
- 24 Sep 2013 9151129 and 9153852 indicate that generic Taxol + carboplatin was the comparator group; NCT and 3088517 say Genexol + carboplatin
- 16 Sep 2013 Data will be presented at the 2013 American Association for Cancer Research (AACR) conference, according to a Sorrento Therapeutics media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History